A.R.T. Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

A.R.T. Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19	Closed	-$46K	–	1493
2019 Q3	$46K	Buy	+19	New	+$55.1K	﹤0.01%	1325

Other funds holding HEPA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

A.R.T. Advisors's HEPA Position: Q4 2019 in Review

A.R.T. Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q4 2019, closing a stake of 19 shares — an estimated $46K sold.

A.R.T. Advisors first reported a position in HEPA in Q3 2019 and held it in 1 quarter. The position peaked at $46K in Q3 2019. 10 funds tracked by Wall St. Rank hold HEPA as of Q4 2019.

A.R.T. Advisors reported no remaining Hepion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 19 Hepion Pharmaceuticals shares in Q4 2019, an estimated $46K.
A.R.T. Advisors first reported a position in Hepion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Hepion Pharmaceuticals position peaked at $46K in Q3 2019.
10 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.